Opioid use was associated with more difficulty falling asleep among adults with chronic pain, according to a recent study. However, this cross-sectional effect was only significant among those reporting lower pain intensity. Researchers speculate that this effect is masked among those with severe pain because the pain-related sleep debt they acquire throughout the night then facilitates sleep onset the next day. Participants (n=144; 95% female; mean age=51.6, SD=11.4) completed assessments of insomnia symptoms, pain, and use of sleep/pain medication. Multiple regression was used to determine if pain intensity moderates the association between opioid use (yes/no) and sleep onset latency (SOL), wake after sleep onset (WASO), sleep quality, or time in bed. They found:
- Stronger pain intensity was associated with longer self-reported WASO and worse sleep quality, independent of opioid use.
- Conversely, opioid use was associated with longer time in bed, independent of pain intensity.
- Opioid use and pain intensity interacted in the prediction of SOL, such that opioid use (vs non-use) was associated with longer SOL in the context of mild but not moderate to severe pain intensity.
Miller MB, Chan WS, Curtis AF, et al. Pain intensity as a moderator of the association between opioid use and insomnia symptoms among adults with chronic pain. [Published online ahead of print September 5, 2018]. Sleep Med. doi:10.1016/j.sleep.2018.08.015.
This Week's Must Reads
Global Burden of Brain and Other CNS Cancers, Lancet Neurol; ePub 2019 Feb 20; GBD 2016 Brain and Other CNS Cancer Collaborators
Ethnoracial Differences Found in Alzheimer Disease, Alzheimers Dement; ePub 2019 Feb 18; Santosa, et al
Must Reads in Pain
Opioid Use, Insomnia, and Pain Intensity, Sleep Med; ePub 2018 Sep 5; Miller, et al
Deployment-Related TBI and Back Pain in Veterans, J Pain; ePub 2018 Aug 30; Suri, Stolzmann, et al
FDA Approves Expanded Use of Exparel Nerve Block, Pacira news release; 2018 Apr 6
FDA Approves Apadaz for Acute Pain Relief, KemPharm, Inc. news release; 2018 Feb 23
FDA Approves Lyrica CR Extended-Release Tablets CV, Pfizer news release; 2017 Oct 12